Browse the evidence

In utero exposure to famine or severe nutritional restriction increases the adult risk of hypertension, type 2 diabetes, and obesity, with risk magnitude dependent on the specific gestational timing of exposure.

If you were born to a mother who experienced severe food scarcity, your body may be biologically primed to store fat and regulate blood sugar differently than average. This is not a character flaw. Focus on consistent, moderate nutritional quality and regular physical activity to support your metabolic health, rather than extreme restrictive diets which may trigger further metabolic adaptation.

Non-coding RNAs (miRNAs, lncRNAs, circRNAs) regulate gene expression in metabolic diseases and serve as diagnostic/prognostic biomarkers and potential therapeutic targets.

Research into non-coding RNAs is leading to new diagnostic tools and potential drugs that can silence or enhance specific genes involved in metabolism, offering hope for treating conditions like obesity and diabetes.

In utero exposure to maternal hyperglycemia (gestational diabetes or elevated glucose levels) independently increases the risk of abnormal glucose tolerance, obesity, and higher blood pressure in offspring by age 7, independent of maternal pre-pregnancy BMI, birth weight, or childhood obesity.

If a mother has gestational diabetes or elevated blood sugar during pregnancy, her child is at a higher risk for metabolic issues like obesity and glucose intolerance by age 7, regardless of the child's birth weight. This risk is biological and programmed in utero. Parents should be aware of this increased risk and prioritize regular metabolic health monitoring (blood pressure, glucose, weight) for their children, especially if there is a family history of diabetes.

PGC-1α regulates ANT1 protein content, which influences submaximal ADP-stimulated respiration and intrinsic mitochondrial function.

Maintaining PGC-1α levels through exercise may support efficient energy exchange in mitochondria, potentially improving metabolic efficiency.

SIRT1 deficiency or inhibition leads to increased hepatic oxidative stress and inflammation by failing to deacetylate FOXO transcription factors and NF-kappaB, promoting the progression from steatosis to steatohepatitis.

Fatty liver isn't just about fat storage; it triggers inflammation and oxidative stress that damage the liver further. SIRT1 helps mitigate this by regulating antioxidant and anti-inflammatory pathways. Maintaining metabolic health supports these protective mechanisms.

Rapamycin inhibits the senescence-associated secretory phenotype (SASP) and reduces SA-β-gal staining in senescent cells through a mechanism independent of the Nrf2 pathway, likely involving Stat3 inhibition.

Rapamycin reduces the harmful inflammatory output (SASP) of aging cells without necessarily stopping them from dividing, and it does this via a pathway separate from the antioxidant response (Nrf2). This suggests that therapies targeting inflammation in aging might not need to address cell cycle arrest directly.

Knocking down Ketohexokinase (KHK), the first enzyme in fructose metabolism, improves hepatic steatosis and glucose tolerance in fructose-supplemented mice.

This paper identifies Ketohexokinase (KHK) as a key enzyme in fructose metabolism. Inhibiting KHK in mice improved liver fat and glucose tolerance. While this suggests a potential future therapeutic target for fatty liver disease, the most immediate action for humans is to reduce fructose intake, especially with high-fat diets.

Occupational exposure to pesticides and biocides is associated with an increased risk of thyroid cancer, particularly in male adults.

Workers in agriculture or pest control should strictly adhere to safety protocols to minimize exposure to pesticides and biocides, as these chemicals are linked to an increased risk of thyroid cancer, particularly in men.

Consumption of branched-chain amino acids (BCAAs) alone does not stimulate muscle protein synthesis or produce an anabolic response in humans; instead, it decreases muscle protein synthesis and turnover.

Taking BCAAs by themselves will not build muscle or increase protein synthesis in humans. In fact, studies show it may actually slow down muscle protein turnover. To build muscle, you need a complete protein source containing all essential amino acids, not just BCAAs.

Healthcare professionals should assess biochemical hyperandrogenism using validated tandem mass spectrometry (LC-MS/MS) for testosterone, avoiding direct immunoassays due to their limited accuracy.

When getting blood work for PCOS, ensure your doctor orders testosterone testing via 'tandem mass spectrometry' (LC-MS/MS). This is the gold standard for accuracy. Avoid standard immunoassays if possible.

Pharmacological or genetic reduction of ceramide synthesis (e.g., via myriocin or CERS6 inhibition) reverses insulin resistance, diabetes, and cardiovascular complications in rodent models.

Research shows that blocking the production of ceramides in animals reverses diabetes and heart disease symptoms. While direct human trials with drugs like myriocin are not detailed here, this suggests that therapies targeting ceramide synthesis could be effective treatments for metabolic diseases in humans.

Abdominal obesity indices (CVAI, NC, WC, WHR, LAP, VAI) are not associated with the prevalence of diabetic retinopathy (DR) in diabetic adults, regardless of BMI adjustment.

Clinicians should not rely on abdominal obesity indices (like CVAI or Neck Circumference) to screen for diabetic retinopathy risk. Regular eye exams remain the gold standard for DR detection, as these body measurements do not correlate with retinal disease prevalence in diabetic patients.

Aging and Alzheimer's disease are associated with impaired glymphatic clearance due to the loss of AQP4 polarization and reduced arterial pulsations.

As you age, your brain's natural waste clearance system becomes less efficient due to structural changes. Prioritizing sleep quality and Omega-3 intake may help mitigate this decline and support the clearance of toxic proteins like amyloid-beta.

In human obesity, elevated circulating leptin levels do not result in weight loss or reduced adiposity due to central leptin resistance, primarily caused by impaired transport across the blood-brain barrier and downstream signaling defects.

Having high leptin levels does not mean your body is successfully managing your weight. In obesity, the brain stops listening to leptin signals due to transport and signaling issues. This is not a permanent genetic sentence but a reversible physiological state. Weight loss can improve leptin sensitivity, breaking the cycle of resistance.

Prenatal exposure to the organochlorine pesticide DDT and its metabolite DDE increases the risk of developing metabolic syndrome (including obesity, insulin resistance, and hypertension) in offspring, primarily through epigenetic programming of energy expenditure and hypothalamic development rather than increased caloric intake.

If you have a family history of metabolic syndrome, consider that your risk may be influenced by environmental exposures your mother encountered during pregnancy, not just your current diet. While you cannot change your prenatal history, being aware of this risk factor allows for earlier screening and more aggressive management of blood pressure and glucose levels, as your body may be predisposed to store fat and resist insulin due to early-life programming.

Accumulation of succinate and itaconate in classically activated macrophages stabilizes HIF-1alpha, which promotes further glycolysis and inflammation, creating a feedback loop.

Specific metabolites (succinate) can act as signaling molecules to lock immune cells into an inflammatory state by stabilizing key transcription factors.

Existing anti-diabetic medications, including Metformin, GLP-1 agonists, and Verapamil, exert part of their therapeutic effect by downregulating TXNIP expression.

If you are taking Metformin or GLP-1 agonists (like Ozempic or Trulicity), one of the reasons they work is that they lower TXNIP levels in your body. This helps your cells use insulin better and protects your pancreas. This is a known mechanism, not a side effect.

Inhibition of the Insulin/IGF-1 signaling (IIS) pathway extends lifespan by promoting the nuclear translocation of the DAF-16/FOXO transcription factor, which then activates downstream genes for stress resistance and longevity.

This research highlights that the body's insulin signaling system acts as a master switch for longevity. In model organisms, reducing the activity of this pathway (mimicking dietary restriction or stress) activates a specific transcription factor (FOXO/DAF-16) that moves to the cell nucleus to turn on protective genes. While this is a mechanistic finding in worms and mice, it suggests that metabolic health and insulin sensitivity are biologically linked to the aging process.

Orexin deficiency is the primary cause of narcolepsy, characterized by a loss of orexin-containing neurons in the lateral hypothalamus.

For individuals with narcolepsy, the underlying cause is often the loss of orexin-producing neurons. Treatments may focus on managing symptoms or potentially replacing orexin signaling, as the system is crucial for maintaining wakefulness.

Exenatide treatment significantly reduces dopamine transporter (DAT) availability in the striatum, caudate, and putamen in patients with Alcohol Use Disorder.

Exenatide changes the brain's dopamine transporter levels in key reward areas, which may help compensate for the dopamine deficits seen in chronic alcohol use. This is a biological mechanism, not a direct measure of drinking behavior.

Tight glucose control (targeting 4.4-6.1 mmol/L) increases mortality in critically ill patients compared to a less strict target (less than 10 mmol/L), and optimal targets may vary based on diabetes status.

Do not use tight glucose control (targeting 4.4-6.1 mmol/L) in critically ill patients. Instead, aim for a less strict target (less than 10 mmol/L) to avoid the increased mortality risk associated with tight control. Consider individualizing targets based on diabetes status.

Inhibition of mTORC1 by rapamycin extends lifespan in multiple species by enhancing autophagy and mitophagy, thereby maintaining mitochondrial homeostasis.

Rapamycin extends lifespan in model organisms by boosting cellular cleanup (autophagy/mitophagy). While effective, chronic use has side effects. Dietary restriction also activates this pathway, offering a natural way to achieve similar benefits without pharmaceutical intervention.

Inhibition of sphingolipid synthesis (specifically via SPT inhibition by myriocin or CerS inhibition by fumonisin B1) extends lifespan in model organisms like yeast and C. elegans, suggesting that reducing ceramide production can delay aging.

Research in simple organisms shows that reducing the production of certain lipids (sphingolipids) can extend lifespan. This suggests that metabolic pathways involving lipid synthesis are key regulators of aging. For humans, this points to the importance of metabolic health and lipid balance, though direct application of inhibitors like myriocin is not currently a standard human intervention.

The novel rapamycin analog DL001 selectively inhibits mTORC1 in vivo without disrupting glucose or lipid homeostasis, unlike conventional rapamycin which causes metabolic side effects via mTORC2 inhibition.

This research identifies a specific compound (DL001) that inhibits the mTORC1 pathway without causing the metabolic side effects (like high blood sugar and bad cholesterol) seen with standard rapamycin. While promising for treating age-related diseases and tuberous sclerosis in future human trials, it is not currently available for general use. The key takeaway is that selective mTORC1 inhibition may be a viable strategy to avoid metabolic disruption.